Keryx Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference
May 05 2015 - 4:30PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that
Greg Madison, the Company's Chief Executive Officer, will be
presenting a company overview, including progress with the
commercialization of Auryxia™ (ferric citrate) in the United
States, at the Bank of America Merrill Lynch 2015 Health Care
Conference, to be held at the Encore at the Wynn in Las Vegas, NV
on May 12-14, 2015.
Mr. Madison's presentation will take place on Thursday, May
13th at 5:00 p.m. PT (8:00 p.m. ET). A live
audio webcast of Mr. Madison's presentation will be accessible
within the Investor Relations section of the Company's website
at http://investors.keryx.com. An archived version of this
webcast will be available following the conclusion of the live
presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston,
is focused on bringing innovative therapies to market for patients
with renal disease. The Company launched its
first FDA-approved product, Auryxia, in the United
States in December 2014. In January 2014, ferric
citrate was approved for the treatment of patients with all stages
of CKD in Japan, where it is being marketed as Riona® by
Keryx's Japanese partner, Japan Tobacco
Inc. and Torii Pharmaceutical Co. Ltd. For more
information about Keryx, please visit www.keryx.com.
CONTACT: Amy Sullivan, Vice President, Corporate Development
and Public Affairs
Keryx Biopharmaceuticals, Inc.
Tel: 617.466.3447
E-mail: amy.sullivan@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024